Phase 1 Study With Sorafenib and Sirolimus

NCT00509613 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

OTHER

Sponsor class

Conditions

Advanced Solid Tumor
Refractory to Standard Therapies

Interventions

DRUG: Sorafenib
DRUG: Sirolimus

Sponsor

Radboud University Medical Center

Collaborators

[object Object]